Available for Licensing
US Patent: US 10512673
Mercedes Gonzalez-Juarrero
Nadya I. Tarasova
Jessy McGowan
Jessy.McGowan@colostate.edu
970-491-7100
At a Glance
Researchers at Colorado State University in collaboration with the Department of Health and Human Services have developed and patented a novel treatment of patients infected with pathogenic bacterial infection or granulomatous disease using peptide-based inhibitors reducing persistent infection by more than 90%.
Background
Current chemotherapy for tuberculosis (TB) fails to eliminate rapidly the Mycobacterium tuberculosis bacilli and to control TB globally. Treatment for drug susceptible TB today requires 6-9 months of multidrug therapy. As for TB patients with multi-drug resistant (MDR) – TB infections, treatment is endured for two years and is unsuccessful in more than 50% of the cases. To improve TB control globally, shorter, effective, and well-tolerated treatments for latent TB infection is desired as this is the only way to reduce the development of resistance against the new chemical entities.
Overview
The treatment encompasses a novel utility for IL-10 and STAT3 peptide inhibitors. Data from animal models demonstrated that both STAT3 N-domain and IL-10R peptide inhibitors significantly reduced the persistent infecting Mycobacterium tuberculosis (Mtb) bacilli load in the lungs and modulated the lung host immune response to enhance its own bactericidal capacity infected with Mtb.
Applications
- Commercially valuable therapeutic approach for targeting persistent infecting Mycobacterium tuberculosis (Mtb) bacilli in the lungs
- TB therapy in combination with current standard chemotherapies
